MetaCap

Celularity Inc. Class A (CELU)

NASDAQ: CELUHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.463-0.0049 (-1.05%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CELU stock chart

Technical analysis

Key statistics

All statistics
Market cap
$15.02M
EPS (TTM)
-$1.69
52-week range
0.42 – 2.55
Day range
0.4202 – 0.4999
Volume / Avg
295.91K / 3.95M
Beta
—

52-week range

$0.42$2.55

CELU stock today

Celularity (CELU) closed at $0.463 on Nov 20, down 1.05% (-$0.0049), versus the S&P 500's 3.70% decline. Trading was light, with 295.91K shares changing hands, about 7% of the average daily volume. Shares are 81.8% below their 52-week high of $2.55, set on Aug 27, 2026 and 10.2% above the 52-week low of $0.42, near the bottom of the past year's range.

CELU is down 58.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 73.5%. Celularity has posted a net loss over the last twelve months (EPS of -$1.69), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Celularity

Company profile

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Robert Joseph Hariri M.D., Ph.D.
Headquarters
Florham Park, NJ
Employees
115
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Celularity generated $26.6 million in revenue, down 51.0% from fiscal 2024, its first annual decline since 2022. Celularity reported a net loss of $91.7 million, compared with a loss of $57.9 million a year earlier. Gross margin was 24.4% (down from 72.4%) and operating margin -230.9%.

Celularity annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$26.55M$54.22M$22.77M$17.98M$21.34M
Growth-51.03%+138.11%+26.68%-15.75%+49.43%
Net income$-91.72M$-57.89M$-196.29M$14.19M$-100.12M
EPS (diluted)$-3.59$-2.64$-11.02$0.95$-1.49

Earnings

Earnings history
Last reported (Sep/2026)
Nov 20, 2026
EPS actual vs est.
$-0.88 vs —

CELU news

All CELU news

Celularity peers

Health Care sector
CELU peer companies
CompanyPrice% ChgMarket capCompare
CNTXContext Therapeutics Inc.0.16-5.10%$14.70Mvs CELU
NCELNewcelX Ltd.2.54-5.58%$14.67Mvs CELU
QNRXQuoin Pharmaceuticals Ltd. ADR3.28-2.35%$15.76Mvs CELU
PBMPsyence Biomedical Ltd.2.97+3.85%$15.80Mvs CELU
ATOSAtossa Therapeutics Inc.1.60-8.86%$15.92Mvs CELU
LPCNLipocine Inc.1.48-1.33%$16.39Mvs CELU
CTXRCitius Pharmaceuticals Inc.0.5085+2.27%$13.96Mvs CELU
SHPHShuttle Pharmaceuticals Holdings Inc.3.49-10.51%$16.63Mvs CELU

Indexes, lists and sector

Celularity stock FAQ

What is Celularity's stock price today?

CELU last traded at $0.463 as of Nov 20, 4:00 PM EST, down 1.05% on the day. Prices are delayed at least 15 minutes.

Does Celularity pay a dividend?

No. Celularity does not currently pay a regular cash dividend.

Who is Celularity's CEO?

Dr. Robert Joseph Hariri M.D., Ph.D. is the chief executive officer of Celularity Inc. Class A, which has about 115 employees.

Has CELU ever split its stock?

Yes. The most recent CELU stock split was a 1-for-10 split on Feb 29, 2024.

What is the CELU 52-week high?

The 52-week high for CELU is $2.55 and the 52-week low is $0.42. The stock is currently 81.8% below its high.

Compare CELU